Oral calcium carbonate as an adjunct to oxytocin infusion for labor induction: a randomized controlled pilot study on feasibility and acceptability

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

This study aimed to assess the feasibility and acceptability of conducting a large randomized controlled trial evaluating the effect of coadministering oral calcium carbonate with synthetic oxytocin infusion during labor induction on labor and delivery outcomes.

Who Took Part

PubMed indexes the participants as adults, women only.

This randomized, controlled, open-label pilot study included nulliparous women with a singleton pregnancy at ≥36 weeks of gestation, a healthy fetus in cephalic presentation, and a planned induction or augmentation of labor with synthetic oxytocin (Pitocin).

Participants were randomized in a 1:1 ratio to receive either synthetic oxytocin alone (control) or oral calcium carbonate coadministered with oxytocin (intervention).

How the Study Was Run

The design is described as randomized, open-label and pilot.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

Everyone knew when Oxytocin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It is described as a pilot, a small early test of whether a larger Oxytocin study would be practical.

Labor characteristics and outcomes were recorded.

The primary outcomes were feasibility and acceptability measures: recruitment, enrollment, and adherence rate to the study protocol.

What Was Measured

The subject headings attached to it are Calcium Carbonate, Oxytocin, Pilot Projects, Labor, Induced, Oxytocics and Feasibility Studies.

Author keywords: labor induction, obstetrics, pilot study, synthetic oxytocin, uterine contractility and vaginal delivery.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Oxytocin.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (American journal of obstetrics & gynecology MFM), a journal based in United States.

More context: the Oxytocin compound page, all human trials.